Efficacy classification of modern therapies in multiple sclerosis
Author:
Affiliation:
1. EVERSANA™, Burlington, ON, Canada
2. EVERSANA™, Sydney, NS, Canada
3. Novartis Pharma AG, Basel, Switzerland
4. Department of Neurology, University Hospital Münster, Westfälische-Wilhelms-University Münster, Münster, Germany
Abstract
Funder
Novartis
Publisher
Future Medicine Ltd
Subject
Health Policy
Link
https://www.futuremedicine.com/doi/pdf/10.2217/cer-2020-0267
Reference60 articles.
1. Multiple sclerosis
2. Defining the clinical course of multiple sclerosis: The 2013 revisions
3. European Medicines Agency. Clinical investigation of medicinal products for the treatment of multiple sclerosis. (2015). https://www.ema.europa.eu/en/clinical-investigation-medicinal-products-treatment-multiple-sclerosis
4. Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
5. Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis
Cited by 56 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Longitudinal enlargement of choroid plexus is associated with chronic lesion expansion and neurodegeneration in RRMS patients;Multiple Sclerosis Journal;2024-02-06
2. Recent trends in disease-modifying therapy use and associated sickness absence and disability pension among people with multiple sclerosis in Sweden;Multiple Sclerosis Journal;2024-01-19
3. University education facilitates uptake of disease-modifying therapies for multiple sclerosis: A community-based study using the UK MS Register;Multiple Sclerosis Journal;2024-01-17
4. Insights for Healthcare Providers on Shared Decision-Making in Multiple Sclerosis: A Narrative Review;Neurology and Therapy;2024-01-05
5. Shared Decision-Making in the Treatment of Multiple Sclerosis: Results of a Cross-Sectional, Real-World Survey in Europe and the United States;Patient Preference and Adherence;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3